The global beta-lactam and beta-lactamase inhibitors market has been categorized as a part of the global pharmaceutical market. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Growth in the global pharmaceutical market will be driven by the factors increasing life expectancy, increasing prevalence of sedentary lifestyle, increase in cases of chronic conditions, etc.
The beta-lactam and beta-lactamase inhibitors market size is expected to grow by USD 9.04 billionfrom 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.44% during the forecast period, according to Technavio.
The report offers an up-to-date analysis of the latest trends and drivers, the current market scenario, and the overall market environment. Request PDF Sample ReportBeta Lactam and Beta Lactamase Inhibitors Market 2022-2026: Scope
The beta-lactam and beta-lactamase inhibitors market report covers the following areas:
- Beta Lactam and Beta Lactamase Inhibitors Market Size
- Beta Lactam and Beta Lactamase Inhibitors Market Trends
- Beta Lactam and Beta Lactamase Inhibitors Market Industry Analysis
Beta Lactam and Beta Lactamase Inhibitors Market 2022-2026: Vendor Landscape
Leading vendors, such as Abbott Laboratories and AbbVie Inc., compete in the market in focus based on pricing, product innovation, and availability of drugs and dietary supplements. Vendors are trying to increase their market share by adopting strategies such as mergers and acquisitions. The regulatory control and exit barrier in the market in focus are high. Therefore, the competition in the market in focus is expected to increase during the forecast period.Beta Lactam and Beta Lactamase Inhibitors Market 2022-2026: Vendor Analysis
Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. are among some of the major market participants.
Find key strategic initiatives used by vendors, along with key news and the latest developments. View our PDF Sample Report NowBeta Lactam and Beta Lactamase Inhibitors Market 2022-2026: Segmentation
- Route of Administration
- Oral – The beta lactam and beta lactamase inhibitors market share growth by the oral segment will be significant during the forecast period. Factors such as increased availability of oral agents with excellent absorption (good bioavailability) that provides adequate blood levels with oral administration and increased pressure on physicians to provide more cost-effective therapies for patients have resulted in increased demand for oral route of administration. This is expected to drive the growth of this segment during the forecast period.
- Intravenous
- Others
- Geography
- North America – 37% of the market’s growth will originate from North America during the forecast period. The easy availability of beta lactam and beta lactamase inhibitors over the counter (OTC) will facilitate the beta lactam and beta lactamase inhibitors market growth in North America over the forecast period
- Europe
- Asia
- ROW (Rest of the World)
To get more insights on segments. Request our Sample PDF ReportBeta Lactam and Beta Lactamase Inhibitors Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist beta lactam and beta lactamase inhibitors market growth during the next five years
- Estimation of the beta lactam and beta lactamase inhibitors market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the beta lactam and beta lactamase inhibitors market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of beta lactam and beta lactamase inhibitors market, vendors
Related Reports:
Home Healthcare Services Market by Application and Geography – Forecast and Analysis 2022-2026
Metaverse in Healthcare Market by Component and Geography – Forecast and Analysis 2022-2026
| Beta Lactam And Beta Lactamase Inhibitors Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 5.44% |
| Market growth 2022-2026 | USD 9.04 billion |
| Market structure | Concentrated |
| YoY growth (%) | 4.29 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 37% |
| Key consumer countries | US, Canada, Denmark, China, and India |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition – Five forces 2021 and 2026
5 Market Segmentation by Route of Administration
- 5.1 Market segments
- Exhibit 24: Chart on Route of Administration – Market share 2021-2026 (%)
- Exhibit 25: Data Table on Route of Administration – Market share 2021-2026 (%)
- 5.2 Comparison by Route of Administration
- Exhibit 26: Chart on Comparison by Route of Administration
- Exhibit 27: Data Table on Comparison by Route of Administration
- 5.3 Oral – Market size and forecast 2021-2026
- Exhibit 28: Chart on Oral – Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Oral – Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Oral – Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Oral – Year-over-year growth 2021-2026 (%)
- 5.4 Intravenous – Market size and forecast 2021-2026
- Exhibit 32: Chart on Intravenous – Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Intravenous – Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Intravenous – Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Intravenous – Year-over-year growth 2021-2026 (%)
- 5.5 Others – Market size and forecast 2021-2026
- Exhibit 36: Chart on Others – Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Others – Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Others – Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Others – Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Route of Administration
- Exhibit 40: Market opportunity by Route of Administration ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America – Market size and forecast 2021-2026
- Exhibit 46: Chart on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America – Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America – Year-over-year growth 2021-2026 (%)
- 7.4 Europe – Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe – Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe – Year-over-year growth 2021-2026 (%)
- 7.5 Asia – Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia – Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia – Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- 7.7 US – Market size and forecast 2021-2026
- Exhibit 62: Chart on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US – Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US – Year-over-year growth 2021-2026 (%)
- 7.8 Denmark – Market size and forecast 2021-2026
- Exhibit 66: Chart on Denmark – Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Denmark – Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Denmark – Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Denmark – Year-over-year growth 2021-2026 (%)
- 7.9 China – Market size and forecast 2021-2026
- Exhibit 70: Chart on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on China – Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on China – Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on China – Year-over-year growth 2021-2026 (%)
- 7.10 Canada – Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada – Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada – Year-over-year growth 2021-2026 (%)
- 7.11 India – Market size and forecast 2021-2026
- Exhibit 78: Chart on India – Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on India – Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on India – Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on India – Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Abbott Laboratories
- Exhibit 89: Abbott Laboratories – Overview
- Exhibit 90: Abbott Laboratories – Business segments
- Exhibit 91: Abbott Laboratories – Key news
- Exhibit 92: Abbott Laboratories – Key offerings
- Exhibit 93: Abbott Laboratories – Segment focus
- 10.4 AbbVie Inc.
- Exhibit 94: AbbVie Inc. – Overview
- Exhibit 95: AbbVie Inc. – Product / Service
- Exhibit 96: AbbVie Inc. – Key offerings
- 10.5 Aristo Pharmaceuticals Pvt Ltd.
- Exhibit 97: Aristo Pharmaceuticals Pvt Ltd. – Overview
- Exhibit 98: Aristo Pharmaceuticals Pvt Ltd. – Product / Service
- Exhibit 99: Aristo Pharmaceuticals Pvt Ltd. – Key offerings
- 10.6 Cipla Ltd.
- Exhibit 100: Cipla Ltd. – Overview
- Exhibit 101: Cipla Ltd. – Business segments
- Exhibit 102: Cipla Ltd. – Key news
- Exhibit 103: Cipla Ltd. – Key offerings
- Exhibit 104: Cipla Ltd. – Segment focus
- 10.7 Dr. Reddys Laboratories Ltd.
- Exhibit 105: Dr. Reddys Laboratories Ltd. – Overview
- Exhibit 106: Dr. Reddys Laboratories Ltd. – Business segments
- Exhibit 107: Dr. Reddys Laboratories Ltd. – Key offerings
- Exhibit 108: Dr. Reddys Laboratories Ltd. – Segment focus
- 10.8 F. Hoffmann La Roche Ltd.
- Exhibit 109: F. Hoffmann La Roche Ltd. – Overview
- Exhibit 110: F. Hoffmann La Roche Ltd. – Business segments
- Exhibit 111: F. Hoffmann La Roche Ltd. – Key news
- Exhibit 112: F. Hoffmann La Roche Ltd. – Key offerings
- Exhibit 113: F. Hoffmann La Roche Ltd. – Segment focus
- 10.9 GlaxoSmithKline Plc
- Exhibit 114: GlaxoSmithKline Plc – Overview
- Exhibit 115: GlaxoSmithKline Plc – Business segments
- Exhibit 116: GlaxoSmithKline Plc – Key news
- Exhibit 117: GlaxoSmithKline Plc – Key offerings
- Exhibit 118: GlaxoSmithKline Plc – Segment focus
- 10.10 Johnson and Johnson
- Exhibit 119: Johnson and Johnson – Overview
- Exhibit 120: Johnson and Johnson – Business segments
- Exhibit 121: Johnson and Johnson – Key news
- Exhibit 122: Johnson and Johnson – Key offerings
- Exhibit 123: Johnson and Johnson – Segment focus
- 10.11 Merck and Co. Inc.
- Exhibit 124: Merck and Co. Inc. – Overview
- Exhibit 125: Merck and Co. Inc. – Business segments
- Exhibit 126: Merck and Co. Inc. – Key news
- Exhibit 127: Merck and Co. Inc. – Key offerings
- Exhibit 128: Merck and Co. Inc. – Segment focus
- 10.12 Pfizer Inc.
- Exhibit 129: Pfizer Inc. – Overview
- Exhibit 130: Pfizer Inc. – Product / Service
- Exhibit 131: Pfizer Inc. – Key news
- Exhibit 132: Pfizer Inc. – Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 133: Inclusions checklist
- Exhibit 134: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 135: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 136: Research methodology
- Exhibit 137: Validation techniques employed for market sizing
- Exhibit 138: Information sources
- 11.5 List of abbreviations
- Exhibit 139: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio